Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage
References (21)
- et al.
Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals
Mut. Res.
(1988) - et al.
Trace analysis of the antineoplastics IF and cyclophosphamide in sewage water by two step solid phase extraction and
J. Chromatogr. A
(1996) - et al.
The Cytotoxics Handbook
(1993) Security data sheet (91/155/EWG) Ifosfamide
(1995)- et al.
Urinary excretion of the enantiomers of IF and its inactive metabolites in children
Cancer Chemother. Pharmacol.
(1991) DIN 38 412 Deutsche Einheitsverfahren zur Wasser-, Abwasser- und Schlammuntersuchung
(1996)- et al.
Biological monitoring of cyclophosphamide and IF in urine of hospital personnel occupationally exposed to cytostatic drugs
Occup. Environ. Med.
(1994) Direction General III, Assessment of potential risks to the environment posed by medical products for human use (excluding products containing live genetically modified organisms)
(1995)- et al.
Determination of the urinary excretion of IF and its phosphorylated metabolites by phosphorous-31 nuclear magnetic resonance spectroscopy
Cancer Chemother. Pharmacol.
(1993) Determination of urinary 2 and 3-dechloroethylated metabolites of IF by high performance liquid chromatography
J. Chromatogr—Biomed. Appl.
(1991)
There are more references available in the full text version of this article.
Cited by (186)
Design and optimization of TiO<inf>2</inf>-based photocatalysts for efficient removal of pharmaceutical pollutants in water: Recent developments and challenges
2024, Journal of Water Process EngineeringAnticancer drugs in the aquatic ecosystem: Environmental occurrence, ecotoxicological effect and risk assessment
2021, Environment International
- †
Present address: Institut für Biologie II, Universität Freiburg, Schänzlestr. 1, D-79104 Freiburg i. Br., Germany.
Copyright © 1997 Published by Elsevier Ltd.